Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(IN THOUSANDS, EXCEPT PER SHARE DATA)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| REVENUES: | ||
| Collaboration revenues | $7,588 | $13,367 |
| Royalties, license and other revenues | 1,357 | 1,336 |
| Total revenues | 8,945 | 14,703 |
| Cost of sales | (671) | (728) |
| Gross profit | 8,274 | 13,975 |
| OPERATING EXPENSES: | ||
| Research and development | 15,705 | 13,987 |
| General and administrative | 17,302 | 22,508 |
| Total operating expenses | 33,007 | 36,495 |
| Loss from operations | (24,733) | (22,520) |
| OTHER INCOME (EXPENSES): | ||
| Interest income, net | 1,629 | 829 |
| Loss on marketable equity securities, net | (176) | (2,194) |
| Gain on revaluation of warrant liability | 2 | 225 |
| Other expenses, net | (4) | (2,152) |
| Total other income (expenses), net | 1,451 | (3,292) |
| LOSS BEFORE INCOME TAXES | (23,282) | (25,812) |
| Provision for income tax benefit (expense) | 1,803 | (541) |
| NET LOSS | (21,479) | (26,353) |
| Net (income) loss attributable to noncontrolling interest | (7) | 80 |
| NET LOSS ATTRIBUTABLE TO LINEAGE | $(21,486) | $(26,273) |
| NET LOSS PER COMMON SHARE ATTRIBUTABLE TO LINEAGE | ||
| Basic and Diluted | $(0.12) | $(0.15) |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | ||
| Basic and Diluted | 172,663 | 169,792 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.